| Bioactivity | BIM 21009 is a LHRH and GnRH receptor antagonist. BIM 21009 inhibits tumor growth[1]. |
| Name | BIM 21009 |
| CAS | 106881-54-3 |
| Sequence | Ac-{d-Nal}-{d-Cl-Phe}-{d-Phe}-Ser-Tyr-{d-Arg}-Phe-Arg-Pro-{d-Ala}-NH2 |
| Shortening | Ac-{d-Nal}-{d-Cl-Phe}-{d-Phe}-SY-{d-Arg}-FRP-{d-Ala}-NH2 |
| Formula | C74H92ClN17O13 |
| Molar Mass | 1463.08 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ban E, Crumeyrolle-Arias M, Latouche J, Leblanc P, Heurtier JF, Drieu K, Fillion G, Haour F. GnRH receptors in rat brain, pituitary and testis; modulation following surgical and gonadotropin-releasing hormone agonist-induced castration. Mol Cell Endocrinol. 1990 Mar 26;70(1):99-107. [2]. Bogden AE,et al. Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res. 1990 May 1;50(9):2646-50. |